Results 161 to 170 of about 105,940 (263)
Neutrophil-to-Lymphocyte Ratio as a Marker of Diabetic Ketoacidosis Severity in Type 1 Diabetes Mellitus: A Retrospective Study. [PDF]
Alduraibi RK +5 more
europepmc +1 more source
Our paper systematically reviews the intestinal structure, function, and microbiota of ostriches, along with strategies for improving their gut health. We analyze how these factors collectively influence intestinal homeostasis and ostrich welfare, emphasizing probiotics as a promising intervention to enhance gut health, boost population well‐being, and
Zi‐Qun Zhang +6 more
wiley +1 more source
S-GRAS score and the complementary prognostic value of neutrophil-to-lymphocyte ratio in adrenocortical carcinoma: evidence for a synergistic interaction. [PDF]
Bényei E +11 more
europepmc +1 more source
Modulation of Animal Gut Health by Milk Oligosaccharide
This review summarizes the composition and structural characteristics of MOs across different mammalian species, and elucidates their roles and mechanisms in maintaining intestinal homeostasis by regulating gut microbiome and enhancing intestinal chemical, physical and immune barriers.
Ningtao Chen +7 more
wiley +1 more source
The neutrophil-to-lymphocyte ratio as a marker of immunosenescence and COVID-19 outcomes in the elderly: A narrative review. [PDF]
Gasmi M +4 more
europepmc +1 more source
Objective Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia +18 more
wiley +1 more source
Correlation between the neutrophil-to-lymphocyte ratio and enlarged perivascular spaces in type 2 diabetes mellitus. [PDF]
Zhang W +5 more
europepmc +1 more source
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava +8 more
wiley +1 more source

